Anemia after kidney transplantation: Does its basis differ from anemia in chronic kidney disease?

Abstract

Background: Although similar factors play a role in both PTA and anemia in patients with CKD, additional risk factors exist in the pathogenesis of PTA. The present study aimed at comparing anemia and inflammation-related parameters between RTx recipients and CKD patients and elucidating the risk factors of PTA. Methods: This single-centered, cross-sectional study consisted of 68 participants: 48 were in the RTx group and 20 were in the CKD group. The CKD patients were comparable to the RTx recipients in terms of age, gender, and eGFR. Serum levels of EPO, hepcidin, and IL-6 were measured by enzyme-linked immunosorbent assays. The ratio of EPO/Hb was calculated to estimate endogenous EPO resistance. Results: The prevalence of anemia was 46% in the RTx group and 30% in the CKD group (P = .23). RTx recipients had significantly lower Hb (P = .04), higher EPO

Anemia in Pediatric Kidney Transplant Recipients—Etiologies and Management

“…In a study of 147 pediatric patients, White et al found higher odds of developing anemia at all stages of CKD in transplant recipients vs. patients with native CKD ( 5 ). Similarly a recent pediatric study by Oruc et al showed lower hemoglobin ( p = 0.04) despite a higher erythropoietin level ( p < 0.001) in transplant recipients compared with GFR-matched native CKD patients ( 35 ). These data suggest that additional mechanisms are at play in the posttransplant population.…”

“…A cross-sectional study of 45 pediatric kidney transplant recipients found a 62% prevalence of CKD stage 3 or higher ( 5 ). Although graft dysfunction is a significant cause of PTA, adult and pediatric data indicate a higher prevalence and greater severity of PTA compared with native CKD for the same level of kidney dysfunction ( 5 , 35 , 36 ). In a study of 147 pediatric patients, White et al found higher odds of developing anemia at all stages of CKD in transplant recipients vs. patients with native CKD ( 5 ).…”

The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study

“…For renal transplantation patients, delayed graft function, allograft rejection, and calcineurin inhibitor toxicity all can induce renal tubular injury, which then leads to decreased EPO secretion in tubules. 43 Treatment with roxadustat can help to relieve inflammation and renal tubular injury, 44 which may be one of the potential mechanisms underlying the effectiveness of roxadustat in treating PTA.…”